GPHN and colorectal cancer: In colorectal cancer, NCOA4 has been identified as the most prevalent partner, accounting for 63% of cases, followed by CCDC6, which accounts for 21% of cases, and GPHN (Gephyrin), accounting for 5% of cases [17].